Company: BDRX
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001214659-25-007913
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-15
Form: 424B3
Chunk 5
---
 Act of 1933, as amended (the “”).

If this offer is accepted and this letter agreement is executed and delivered to the Company on or before 9:00 a.m. (New York City time) on May 22, 2025, the Company shall (i) file a prospectus supplement to the Registration Statements, as applicable, with the Securities and Exchange Commission ("SEC") disclosing the reduced exercise price of the Warrants, and (ii) file a Current Report on Form 6-K (the "Form 6-K") with the SEC disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto with the SEC within the time required by the Exchange Act of 1934, as amended. From and after the issuance of the Form 6-K, the Company represents to the Holder that it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company or any of its officers, directors, employees or agents in connection with the transactions contemplated hereby. In addition, effective upon the issuance of the Form 6-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and the Holder or any of its Affiliates on the other hand, as it relates to the transaction described herein, shall terminate. The Company represents to the Holder that none of the Company's directors, officers, employees or agents will provide the Holder with any material, nonpublic information that is not disclosed in the Form 6-K.

The closing of the transaction
described herein shall occur no later than May 19, 2025, at 9:00 a.m. (New York City Time) at such location as the parties shall mutually
agree (the “”). Unless otherwise directed by the Company, settlement of the Warrant Exercise hereunder
shall occur via “Delivery Versus Payment” (“”) (i.e., on the Closing Date, the Company shall issue the
American Depositary Shares issued in the Warrant Exercise in the Holder’s name and address and be released by the transfer agent
or depositary directly to the account(s) identified by the Holder; and upon receipt of such Warrant Shares, the payment of the aggregate
exercise price therefor shall be made by the Holder by wire transfer to the Company). On or prior to the Closing Date, the Holder shall